---
title: "Acacia Research | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 114.56 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294954884.md"
datetime: "2026-08-05T11:04:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294954884.md)
  - [en](https://longbridge.com/en/news/294954884.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294954884.md)
---

# Acacia Research | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 114.56 M

Revenue: As of FY2026 Q2, the actual value is USD 114.56 M, beating the estimate of USD 49.5 M.

EPS: As of FY2026 Q2, the actual value is USD 0.

EBIT: As of FY2026 Q2, the actual value is USD 7.687 M.

The provided Form 8-K filing by Acacia Research Corporation announces the issuance of a press release regarding its financial results for the quarter ended June 30, 2026. However, the actual financial and operational metrics, including segment revenue, net income, gross margin, operating profit, cash flow, or any company-specific indicators, are not detailed within the provided text of the Form 8-K. Additionally, the reference does not include any outlook or guidance content.

### Related Stocks

- [ACTG.US](https://longbridge.com/en/quote/ACTG.US.md)

## Related News & Research

- [Acacia Research (NASDAQ:ACTG) Releases Quarterly Earnings Results, Beats Estimates By $0.22 EPS](https://longbridge.com/en/news/295014533.md)
- [Why Cameco's ugly earnings miss might be good news in disguise](https://longbridge.com/en/news/295306152.md)
- [Progress Toward Reopening the Strait of Hormuz Weighs on Oil Prices](https://longbridge.com/en/news/295003365.md)
- [Ensysce Biosciences posts investor presentation spotlighting trypsin-controlled opioid platforms, pain pipeline](https://longbridge.com/en/news/295107304.md)
- [15:00 ETJosh Allen National Treasures Rookie Patch Autograph 1/1 Sells for $1.7 Million, a Record for Any Josh Allen Card](https://longbridge.com/en/news/295134427.md)